Entities / Company
Revvity.
American biotech company
- Reports this week
- 0
- Active events
- 0
- Connections
- 40
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Zacks Research reduced earnings per share estimates for Revvity and Team on August 27, 2026.Some support2 reports
-
Revvity and Codexis, both healthcare companies, are currently competing against each other for market share.Some support2 reports
-
Dovish remarks made on September 3, 2025, eased market concerns regarding high interest rates, involving the FED and Jerome Powell.Well supported52 reports21 developments inside
-
Revvity acquired Human Cell Design on September 11, 2026, aligning HCD models with Revvity's portfolio.Some support1 report
-
Manufacturers Life Insurance Company purchased a new stake in Revvity shares.Some support2 reports
-
Revvity announced on September 1, 2026, that it provides solutions across the Americas, Europe, and Asia.Some support1 report
Gone quiet
No new reports in 90+ days-
Revvity agreed to sell its China Immunodiagnostics and ACD/Labs software business units, contributing to Q2 revenue growth.Some support2 reports
-
Both Revvity and Evotec are healthcare companies operating in the biotech sector.Some support3 reports
-
Revvity stock was traded on the New York Stock Exchange.Some support1 report
-
Revvity was listed on the New York Stock Exchange, and TD Cowen subsequently restated its buy rating on the company's shares.Some support2 reports
-
Revvity's CEO noted that the operating environment in China's diagnostics sector is dynamic due to regulatory headwinds and reduced test volumes.Some support4 reports
-
ADC and Revvity are involved in accelerating the development of Antibody-Drug Conjugate (ADC) therapeutics.Some support1 report
-
The FDA approved an automated platform for the T-SPOT test, and a partnership was established to enhance newborn genomic screening services.Some support1 report
-
Revvity is identified as a leading company in the MedTech sector.Some support2 reports
-
Revvity's stock underperformed the S&P 500 on August 18, 2025.Some support4 reports
-
Historical corporate facts detail the formation of DXC Technology and the rebranding of PerkinElmer to Revvity.Some support6 reports
-
Revvity has been using LinkedIn since August 18, 2025, to keep company stakeholders updated.Some support3 reports
-
Dassault Systèmes and Revvity are featured leaders in the ELN market.Some support1 report
-
Kevin Quick was appointed Vice President of Platforms, Life Sciences at Revvity.Some support1 report
-
Stifel lowered price targets on Revvity stock on September 4, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Revvity this week
News at the entities that move Revvity most-
Manufacturers Life Insurance Company StructuralGeode Capital Management, Mizuho Securities, and Manufacturers Life Insurance Company increased their holdings and raised their target price/rating on MBX Biosciences stock.Moves Revvity
-
Singh StructuralSingh led city efforts for community benefits and postponed a 305-home subdivision review in Manteca.Moves Revvity
-
FDA StructuralFDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.Moves Revvity
-
New York Stock Exchange StructuralLazard Asset Management LLC lifted its position in the stock of General American Investors, Inc., which is listed on the NYSE.Moves Revvity
-
TD Cowen Mentioned togetherJefferies raised its price objective on Aflac shares, while Barclays and TD Cowen issued rating updates.Moves Revvity
-
representative TransactionalA representative is facing pressure to satisfy constituents' expectations.Moves Revvity
Connections
The 16 strongest of 40, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
PerkinElmer Structural
Revvity is the current name of PerkinElmer, established through a rebranding event in 2023.
-
Manufacturers Life Insurance Company Structural
Manufacturers Life Insurance Company holds an increasing ownership stake in Revvity.
-
Singh Structural
Singh serves as the CEO of Revvity.
-
FDA Structural
FDA formally regulates and approves products and platforms developed by Revvity.
-
representative Transactional
Representative purchased and subsequently sold shares of Revvity Inc.
-
New York Stock Exchange Structural
Revvity is formally listed on the New York Stock Exchange, establishing a structural dependency.
-
Codexis Operational
Both companies are actively competing for market share within the healthcare sector.
-
TD Cowen Mentioned together
TD Cowen provides analyst ratings and market coverage for Revvity.
Show all 16 connections
-
LinkedIn Operational
Revvity actively uses LinkedIn as a platform to stay updated on industry developments.
-
Cytokinetics Mentioned together
Both Revvity and Cytokinetics are identified as publicly traded biotech companies.
-
MarketBeat Structural
MarketBeat provides analyst ratings and market coverage for Revvity, creating a functional dependency for market visibility.
-
YETI Mentioned together
Both Revvity and YETI are publicly traded companies.
-
Ultragenyx Pharmaceutical Mentioned together
Both Revvity and Ultragenyx Pharmaceutical are identified as publicly traded biopharma companies.
-
Evotec Shared context
Both companies operate within the shared context of the competitive biotech healthcare sector.
-
Americas Shared context
Revvity operates within the geographical region of the Americas.
-
Team Mentioned together
Evidence is insufficient to determine a specific relationship between the two companies.
History
Events by the month they beganSeptember 2026
3 events- Revvity and Codexis, both healthcare companies, are currently competing against each other for market share.
- Revvity acquired Human Cell Design on September 11, 2026, aligning HCD models with Revvity's portfolio.
- Revvity announced on September 1, 2026, that it provides solutions across the Americas, Europe, and Asia.
August 2026
5 events- Zacks Research reduced earnings per share estimates for Revvity and Team on August 27, 2026.
- Manufacturers Life Insurance Company purchased a new stake in Revvity shares.
- Revvity agreed to sell its China Immunodiagnostics and ACD/Labs software business units, contributing to Q2 revenue growth.
- Both Revvity and Evotec are healthcare companies operating in the biotech sector.
- Revvity stock was traded on the New York Stock Exchange.
July 2026
1 eventShow 1 earlier month
June 2026
11 events- Dovish remarks made on September 3, 2025, eased market concerns regarding high interest rates, involving the FED and Jerome Powell.
- Revvity's CEO noted that the operating environment in China's diagnostics sector is dynamic due to regulatory headwinds and reduced test volumes.
- ADC and Revvity are involved in accelerating the development of Antibody-Drug Conjugate (ADC) therapeutics.
- The FDA approved an automated platform for the T-SPOT test, and a partnership was established to enhance newborn genomic screening services.
- Revvity is identified as a leading company in the MedTech sector.
- Revvity's stock underperformed the S&P 500 on August 18, 2025.
- Historical corporate facts detail the formation of DXC Technology and the rebranding of PerkinElmer to Revvity.
- Revvity has been using LinkedIn since August 18, 2025, to keep company stakeholders updated.
- Dassault Systèmes and Revvity are featured leaders in the ELN market.
- Kevin Quick was appointed Vice President of Platforms, Life Sciences at Revvity.
- Stifel lowered price targets on Revvity stock on September 4, 2025.